Petr Jarolim, Ph.D., M.D.
Co-Author
This page shows the publications co-authored by Petr Jarolim and David Berg.
Connection Strength
1.444
-
Serial Assessment of High-Sensitivity Cardiac Troponin and the Effect of Dapagliflozin in Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of the DAPA-HF Trial. Circulation. 2022 01 18; 145(3):158-169.
Score: 0.242
-
A Biomarker-Based Score for Risk of Hospitalization for Heart Failure in Patients With Diabetes. Diabetes Care. 2021 11; 44(11):2573-2581.
Score: 0.240
-
A Targeted Proteomic Approach Identifies Novel Biomarkers of Arterial Thromboembolic Risk in ENGAGE AF-TIMI 48. J Am Coll Cardiol. 2021 08 10; 78(6):634-636.
Score: 0.238
-
Cardiovascular Biomarkers and Heart Failure Risk in Stable Patients With Atherothrombotic Disease: A Nested Biomarker Study From TRA 2°P-TIMI 50. J Am Heart Assoc. 2021 05 04; 10(9):e018673.
Score: 0.233
-
Biomarkers of platelet activation and cardiovascular risk in the DAPT trial. J Thromb Thrombolysis. 2021 Apr; 51(3):675-681.
Score: 0.232
-
Performance of the ABC Scores for Assessing the Risk of Stroke or Systemic Embolism and Bleeding in Patients With Atrial Fibrillation in ENGAGE AF-TIMI 48. Circulation. 2019 02 05; 139(6):760-771.
Score: 0.200
-
Serial assessment of biomarkers and the risk of stroke or systemic embolism and bleeding in patients with atrial fibrillation in the ENGAGE AF-TIMI 48 trial. Eur Heart J. 2021 05 01; 42(17):1698-1706.
Score: 0.058
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.